In order to move forward, it is expected that existing data from the Phase 2b/3 Anavex 2-73 AD-004 program be submitted to the FDA. In December, as expected, the CHMP adopted a negative opinion on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results